Literature DB >> 7876846

Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria.

S J Collins1, J E Ahlskog, J E Parisi, D M Maraganore.   

Abstract

All cases examined postmortem at the Mayo Clinic that met the classic neuropathological criteria for progressive supranuclear palsy (PSP) were identified for retrospective clinical analyses. The necropsy material was re-examined by a second neuropathologist to confirm the pathological diagnosis of PSP, yielding 12 cases. A range of clinical signs were documented in these patients, with numerous findings beyond those noted in the original descriptions of this disorder. Atypical clinical findings included absence of supranuclear gaze palsy (two cases), prominent asymmetry (two), arm dystonia (two), upper limb apraxia (two), myoclonus (two), chorea (one), eyelid opening apraxia (one), and respiratory disturbance (one). A definite clinical diagnosis of PSP had been made during life in only eight of the 12 patients. From the retrospective analysis of these 12 cases, a set of clinical criteria were developed for the premortem diagnosis of PSP emphasising differences from other akinetic-rigid disorders.

Entities:  

Mesh:

Year:  1995        PMID: 7876846      PMCID: PMC1073312          DOI: 10.1136/jnnp.58.2.167

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  25 in total

1.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

2.  Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes.

Authors:  M B Stern; B H Braffman; B E Skolnick; H I Hurtig; R I Grossman
Journal:  Neurology       Date:  1989-11       Impact factor: 9.910

3.  Corticobasal degeneration.

Authors:  W R Gibb; P J Luthert; C D Marsden
Journal:  Brain       Date:  1989-10       Impact factor: 13.501

4.  Observations on the efficacy of L-dopa in progressive supranuclear palsy.

Authors:  H L Klawans; S P Ringel
Journal:  Eur Neurol       Date:  1971       Impact factor: 1.710

5.  Further observations in progressive supranuclear palsy.

Authors:  N J David; E A Mackey; J L Smith
Journal:  Neurology       Date:  1968-04       Impact factor: 9.910

6.  Parkinsonism and extraocular motor abnormalities with unusual neuropathological findings.

Authors:  V P Calabrese; M G Hadfield
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

7.  Ageing and Parkinson's disease: substantia nigra regional selectivity.

Authors:  J M Fearnley; A J Lees
Journal:  Brain       Date:  1991-10       Impact factor: 13.501

8.  Corticodentatonigral degeneration with neuronal achromasia.

Authors:  J J Rebeiz; E H Kolodny; E P Richardson
Journal:  Arch Neurol       Date:  1968-01

9.  Diffuse Lewy body disease presenting with a supranuclear gaze palsy.

Authors:  J M Fearnley; T Revesz; D J Brooks; R S Frackowiak; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154

10.  Autonomic involvement in extrapyramidal and cerebellar disorders.

Authors:  P Sandroni; J E Ahlskog; R D Fealey; P A Low
Journal:  Clin Auton Res       Date:  1991-06       Impact factor: 4.435

View more
  47 in total

1.  Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy.

Authors:  A Padovani; B Borroni; S M Brambati; C Agosti; M Broli; R Alonso; P Scifo; G Bellelli; A Alberici; R Gasparotti; D Perani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

2.  Survival and Progression in Synucleinopathy Phenotypes With Parkinsonism: A Population-Based Study.

Authors:  Rodolfo Savica; Pierpaolo Turcano; James H Bower; J Eric Ahlskog; Michelle M Mielke
Journal:  Mayo Clin Proc       Date:  2019-08-09       Impact factor: 7.616

3.  Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Bradley F Boeve; Jonathan Graff-Radford; Walter A Rocca; Michelle M Mielke
Journal:  JAMA Neurol       Date:  2017-07-01       Impact factor: 18.302

4.  Responsiveness of dysphagia to acute L-Dopa challenge in progressive supranuclear palsy.

Authors:  Sara Varanese; Paolo Di Ruscio; Leila Ben M' Barek; Astrid Thomas; Marco Onofrj
Journal:  J Neurol       Date:  2014-01-12       Impact factor: 4.849

Review 5.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010.

Authors:  Pierpaolo Turcano; Michelle M Mielke; Keith A Josephs; James H Bower; Joseph E Parisi; Bradley F Boeve; Rodolfo Savica
Journal:  Mov Disord       Date:  2017-08-26       Impact factor: 10.338

7.  Cholinergic cortical circuits in Parkinson's disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study.

Authors:  Raffaele Nardone; Igor Florio; Piergiorgio Lochner; Frediano Tezzon
Journal:  Exp Brain Res       Date:  2005-03-08       Impact factor: 1.972

8.  Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.

Authors:  M Asahina; T Suhara; H Shinotoh; O Inoue; K Suzuki; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

9.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

Authors:  I Litvan; C A Mangone; A McKee; M Verny; A Parsa; K Jellinger; L D'Olhaberriague; K R Chaudhuri; R K Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

10.  Slow vertical saccades in the frontotemporal dementia with motor neuron disease.

Authors:  S Y Moon; B H Lee; S W Seo; S J Kang; D L Na
Journal:  J Neurol       Date:  2008-09-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.